IntelGenx Technologies Corp.
IGX
Classifica tra le azioni
#28108
IntelGenx Technologies Corp. is a pharmaceutical drug delivery enterprise... IntelGenx Technologies Corp. is a pharmaceutical drug delivery enterprise focused on the creation and manufacturing of advanced oral thin film products. The company's diverse product pipeline encompasses various oral film formulations designed to address a wide spectrum of medical conditions. These include INT0008/2008, a Rizatriptan film for migraine management; INT0046/2018 for adult applications; INT0007/2006, an oral film targeting erectile dysfunction; INT0043/2015, a montelukast-based film for Alzheimer's disease; INT0027/2011, intended for opioid addiction treatment; INT0010/2006, addressing neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, formulated for schizophrenia or bipolar I disorder; and INT0048/2020, developed for veterinary health. Additionally, IntelGenx is actively developing other candidates identified as INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has established strategic partnerships, including a comprehensive licensing, development, and supply agreement with Tilray, Inc., alongside a development pact with Cynapsus Therapeutics Inc. Founded in 2003, IntelGenx Technologies Corp. is headquartered in Montreal, Canada.
Prezzo delle azioni
$0.17446996
Ultima sincronizzazione: 2024-06-11
Capitalizzazione di mercato
$26.97M
Variazione (1 giorno)
-0.57%
Variazione (1 anno)
2.63%
Paese
CA
Scambia IntelGenx Technologies Corp. (IGX)
Categoria
Healthcare
Rapporto P/S per IntelGenx Technologies Corp. (IGX)
Rapporto P/S al October 2026 TTM: 28.58
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di IntelGenx Technologies Corp., il rapporto P/S attuale (TTM) è 28.58. Alla fine del 2022, era pari a 34.22.
Storico del rapporto P/S per IntelGenx Technologies Corp. da 2003 a 2026
Rapporto P/S alla fine di ogni anno
| Anno | Rapporto P/S | Cambia |
|---|---|---|
| 2026 (TTM) | 28.58 | 23.07% |
| 2023 | 23.22 | -32.14% |
| 2022 | 34.22 | 6.49% |
| 2021 | 32.13 | 107.95% |
| 2020 | 15.45 | -73.92% |
| 2019 | 59.24 | 169.97% |
| 2018 | 21.94 | 118.14% |
| 2017 | 10.06 | 5.26% |
| 2016 | 9.56 | 47.40% |
| 2015 | 6.48 | -67.26% |
| 2014 | 19.80 | -37.94% |
| 2013 | 31.91 | 19.48% |
| 2012 | 26.71 | -50.24% |
| 2011 | 53.68 | 480.44% |
| 2010 | 9.25 | -22.24% |
| 2009 | 11.89 | -1.53% |
| 2008 | 12.08 | -21.39% |
| 2007 | 15.36 | -59.29% |
| 2006 | 37.74 | 0.00% |
| 2005 | 0.00 | 0.00% |
| 2004 | 0.00 | 0.00% |
| 2003 | 0.00 | 0.00% |
Rapporto P/S per aziende simili o concorrenti
| Azienda | Rapporto P/S | Differenza del rapporto P/S | Il paese |
|---|---|---|---|
| 10.02 | -64.93% |
US
|
|
| 40.55 | 41.90% |
US
|
|
| 3.96 | -86.14% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -64.50% |
NL
|
